{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:31:47Z","timestamp":1779114707987,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100200700037C"],"award-info":[{"award-number":["HHSO100200700037C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jvacx.2024.100431","type":"journal-article","created":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T10:03:11Z","timestamp":1704621791000},"page":"100431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Compatible co-administration of BioThrax\u00ae vaccine and ciprofloxacin\u2014Results of a randomized open-label drug-vaccine interaction trial"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-7768","authenticated-orcid":false,"given":"David","family":"Cassie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Longstreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka","family":"Hunter-Stitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-6446","authenticated-orcid":false,"given":"Bojan","family":"Drobic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100431_b0005","unstructured":"CDC, Centers for Disease Control [Internet]. The Threat of an Anthrax Attack accessed at: https:\/\/www.cdc.gov\/anthrax\/bioterrorism\/threat.html. Last updated 20Nov2020."},{"key":"10.1016\/j.jvacx.2024.100431_b0010","doi-asserted-by":"crossref","unstructured":"Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerging Infectious Diseases. 2001 Nov-Dec;7(6):933-944.","DOI":"10.3201\/eid0706.010604"},{"key":"10.1016\/j.jvacx.2024.100431_b0015","doi-asserted-by":"crossref","unstructured":"Jernigan, Daniel B; Raghunathan, Pratima L; Bell, Beth P; Brechner, Ross; Bresnitz, Eddy A; Butler, Jay C; et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerging Infectious Diseases. 2002. Volume 8(10):1019-1028.","DOI":"10.3201\/eid0810.020353"},{"key":"10.1016\/j.jvacx.2024.100431_b0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100431_b0025","unstructured":"Use of Anthrax Vaccine in the United States. Advisory Committee on Immunization Practices, MMWR, December 15, 2000 \/ 49 (RR15); 1-20."},{"issue":"7","key":"10.1016\/j.jvacx.2024.100431_b0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/377738","article-title":"Serious Adverse Events among Participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for Persons at Risk for Bioterrorism-Related Inhalational Anthrax","volume":"37","author":"Tierney","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100431_b0035","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vac Immun"},{"issue":"19","key":"10.1016\/j.jvacx.2024.100431_b0040","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.vaccine.2014.01.073","article-title":"Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax\u00ae regimen for post-exposure prophylaxis in healthy adults","volume":"32","author":"Hopkins","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100431_b0045","unstructured":"BioThrax\u00ae (Anthrax Vaccine Adsorbed) United States prescribing information. November 2015."},{"key":"10.1016\/j.jvacx.2024.100431_b0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2307\/2530666","article-title":"Testing the statistical certainty of a response to increasing doses of a drug","volume":"41","author":"Tukey","year":"1985","journal-title":"Biometrics"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:11:16Z","timestamp":1762913476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"alternative-id":["S2590136224000044"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100431","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compatible co-administration of BioThrax\u00ae vaccine and ciprofloxacin\u2014Results of a randomized open-label drug-vaccine interaction trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100431"}}